– DENMARK, Hellerup – Ascendis Pharma A/S (NASDAQ: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create product candidates that address unmet medical needs, today announced the intention of its Board of Directors to appoint current board member, Dr. Albert Cha, to serve as Chair to succeed Michael Jensen who informed the Board that he will not stand for re-election to the Board at the next 2021 AGM.
Mr. Jensen has served as Director and Chair of Ascendis Pharma since January 2008 and as SVP and Chief Legal Officer since 2013. Mr. Jensen will continue in his role as SVP and Chief Legal Officer of Ascendis.
“On behalf of the Board, we thank Michael for his service as Chair for almost 13 years,” said Dr. Albert Cha. “Under his guidance, Ascendis transformed from an early-stage biopharmaceutical company to a global biopharmaceutical company. I am honored the Board intends to nominate me as the next Chair for Ascendis and the opportunity to provide counsel and guidance to executive management during the company’s next stage of growth.”
“It has been my privilege to serve as Chair of Ascendis Pharma for more than a decade,” said Mr. Jensen. “With the company transitioning from a developmental stage company to a global commercial organization, I want to focus my efforts on serving my role as the Chief Legal Officer given the increasing legal complexities of a multi-national biopharmaceutical corporation.”
About Dr. Albert Cha
Albert Cha, M.D., Ph.D. has served as a member of the Ascendis Board since November 2014. Dr. Cha previously was a managing partner at Vivo Capital, a healthcare investment firm. He currently serves as a member of the board of directors of KalVista Pharmaceuticals, Inc. (Nasdaq: KALV). Dr. Cha holds a B.S. and an M.S. from Stanford University and an M.D. and a Ph.D. from the University of California at Los Angeles.
About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative TransCon technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science, and passion, the company utilizes its TransCon technologies to create new and potentially best-in-class therapies.
Ascendis Pharma currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus. The company continues to expand into additional therapeutic areas to address unmet patient needs.
Ascendis is headquartered in Copenhagen, Denmark, with additional offices in Heidelberg and Berlin, Germany, and in Palo Alto and Redwood City, California.
For more information: https://ascendispharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
